← Back to Screener
Alumis Inc. Common Stock (ALMS)
Price$19.06
Value ScoreD
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)140.58%
Price vs S&P 500 (4W)-19.43%
VGM Score41.05
Market Capitalization$2.43B
All Metrics
Book Value / Share (Quarterly)$4.46
P/TBV (Annual)4.07x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-2.97
Price vs S&P 500 (YTD)87.13%
Net Profit Margin (TTM)-1013.23%
EPS (TTM)$-1.93
10-Day Avg Trading Volume1.00M
EPS Excl Extra (TTM)$-1.93
EPS (Annual)$-2.86
ROI (Annual)-80.76%
Cash / Share (Quarterly)$4.11
ROA (Last FY)-59.07%
EBITD / Share (TTM)$-2.53
Operating Margin (TTM)-1109.09%
Cash Flow / Share (Annual)$-3.54
P/B Ratio4.29x
P/B Ratio (Quarterly)4.94x
Net Income / Employee (Annual)$-1,101,000
EV / Revenue (TTM)101.04x
ROA (TTM)-43.57%
EPS Incl Extra (Annual)$-2.86
Current Ratio (Annual)4.34x
Quick Ratio (Quarterly)7.42x
3-Month Avg Trading Volume1.31M
52-Week Price Return468.96%
Revenue / Employee (TTM)$108,800
Tangible BV / Share (Quarterly)$4.06
P/S Ratio (Annual)101.04x
Asset Turnover (Annual)0.06x
52-Week High$30.60
EPS Excl Extra (Annual)$-2.86
26-Week Price Return148.50%
Quick Ratio (Annual)4.24x
13-Week Price Return-31.04%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)7.51x
Enterprise Value$2.43B
Asset Turnover (TTM)0.05x
Revenue / Employee (Annual)$108,800
Pretax Margin (Annual)-1047.34%
Cash / Share (Annual)$2.95
3-Month Return Std Dev71.50%
Net Income / Employee (TTM)$-1,075,700
ROE (Last FY)-80.76%
EPS Basic Excl Extra (Annual)$-2.86
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.93
ROI (TTM)-54.71%
P/S Ratio (TTM)101.04x
Revenue / Share (Annual)$0.28
Tangible BV / Share (Annual)$2.39
Price vs S&P 500 (52W)444.59%
Year-to-Date Return95.29%
5-Day Price Return-6.25%
EPS Normalized (Annual)$-2.86
Net Profit Margin (Annual)-1011.75%
Month-to-Date Return-11.76%
EBITD / Share (Annual)$-3.09
Operating Margin (Annual)-1105.60%
EPS Basic Excl Extra (TTM)$-1.93
P/TBV (Quarterly)5.43x
P/B Ratio (Annual)3.38x
Pretax Margin (TTM)-1046.50%
Book Value / Share (Annual)$2.88
Price vs S&P 500 (13W)-39.30%
Beta0.83x
Revenue / Share (TTM)$0.23
ROE (TTM)-54.71%
52-Week Low$2.76
vGradeD
mGradeB
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.74est. -0.78
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.36
4.40
4.41
4.41
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ALMSAlumis Inc. Common Stock | D | — | B | $19.06 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Alumis Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for autoimmune disorders. Leveraging its proprietary precision data analytics platform, the company aims to replace broad immunosuppression with more specific therapeutic approaches. Its pipeline includes drug candidates targeting TYK2 and IRF5 pathways.